Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep aid boosts immunity in small trial

NCT ID NCT07414381

Symptom relief Sponsor: Shanghai Cell Therapy Group Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a product called Chenghuang Circadian Rhythm Regulator in 15 adults with ongoing sleep problems. The goal was to see if it could improve sleep quality and immune markers. Results are not yet reported, but the study was small and had no comparison group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Jun 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects complain about significant distress or impairment in social functioning caused by poor sleep; * Following sleep problems happened ≥ 3 times a week and last for ≥ 1 month: 1. Difficult in sleep onset: sleep actigraphy device report sleep latency ≥ 30 mins; 2. Or difficult in sleep maintenance: nighttime awakenings ≥2 times; or early morning awakenings; or total sleep duration \< 6 hours; or abnormal deep reported by actigraphy device; * Pittsburgh Sleep Quality Index(PSQI) global score \>7; * Subjects voluntarily agree to participate in this study and have signed the informed consent form. Exclusion Criteria: * Subjects with coagulation dysfunction, severe cardiovascular and cerebrovascular, hepatic, renal, hematological disorders, or psychiatric diseases; * Pregnant or lactating women; * Subjects with secondary sleep disorders (e.g., due to depression, anxiety, sleep apnea syndrome, etc.); * Subjects who received acupuncture, hypnotics or cognitive behavioral therapy for sleep disorder within past 4 weeks; * Subjects with shift work or a history of transmeridian travel within the past 4 weeks; * Subjects with diseases, medication use, or swallowing difficulties that may affect gastrointestinal absorption or motility; * Subjects with diseases or abnormalities assessed by the investigator to potentially affect study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sleep disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sleep disorders

Contacts and locations

Locations

  • Shanghi Mengchao Cancer Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.